Skip to content

Brain Imaging Study on Biomarkers for Chronic Back Pain

Brain Imaging Study on Biomarkers for Chronic Back Pain

Status
Enrolling by invitation
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02991625
Enrollment
250
Registered
2016-12-13
Start date
2018-01-22
Completion date
2035-01-31
Last updated
2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Back Pain

Brief summary

The study proposes to investigate the factors related to a person that can enhance or reduce the effectiveness of pain treatments in people suffering with chronic pain. Treatment response to pain killers in a person may be related to their brain, genetics, social, and psychological makeup. The investigators aim to study these factors to identify and develop feasible and robust indicators based on a person's biological makeup (also called biomarkers).

Detailed description

Drugs used for managing chronic pain have not proven to be effective and chronic pain continues to cost Canadians $60 billion a year without truly helping those who suffer. The study proposes to investigate the factors related to a person that can enhance or reduce the effectiveness of pain treatments in people suffering with chronic pain. Treatment response to pain killers in a person may be related to their brain, genetics, social, and psychological makeup. The investigators aim to study these factors to identify and develop feasible and robust indicators based on a person's biological makeup (also called biomarkers). These biomarkers will allow doctors and researchers to predict more accurately which treatment and prevention strategies for a particular disease will work in which groups of people. These measures will offer new opportunities for improving treatment such as by tailoring treatment to meet the specific needs of each patient based on his/her biological and psychological makeup. Towards the specific aim, data will first be collected in several experimental domains for studying treatment expectations (cognitive, psychosocial, brain-related, genetic). These 'experimental' data will be compared between chronic back pain (CBP) and healthy participants to yield new understanding of the factors that govern treatment response. At the end of experimental data collection, the investigators will collect data in the 'clinical' domain. Hence, at the end of the experimental sessions, a subset of CBP participants will receive a mock drug (placebo disguised as an approved pain treatment) and another subset will provide pain ratings only and hence serve as a waiting list control for the placebo trial. Data will be studied in steps to understand factors that mediate treatment outcomes and finally the investigators will use advanced computational tools used for big data analysis and aim to identify factors that can be used as biomarkers and precision medicine tools.

Interventions

OTHERPlacebos

Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.

OTHERWaitlist

These Chronic Back Pain participants will not be given any placebos and will be requested to report their pain on paper forms organized as a calendar.

OTHERHealthy Controls

Healthy control participants will not receive a placebo drug or be put on a waitlist.

Sponsors

Nova Scotia Health Authority
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

Chronic pain participant inclusion criteria: 1. 18-75 years of age 2. Right-handed 3. Meet the classification criteria of chronic low back pain (having low back pain for more than 6 months), as determined by a physician and documented in the participant's medical record. 4. At least 4/10 clinical pain on the Brief Pain Inventory Scale on average during the two weeks prior to enrollment 5. Comfortable completing (reading and writing) questionnaires and tasks with English language instructions Healthy participant inclusion criteria: 1. 18 - 75 years of age 2. Right-handed 3. Comfortable completing (reading and writing) questionnaires and tasks with English language instructions

Exclusion criteria

Chronic pain participant

Design outcomes

Primary

MeasureTime frameDescription
Pain modulation - using an experimental task that tests a person's ability to form positive expectations3 days after first visitBrain imaging will be used to assess each participant's capacity to endogenously adjust pain perception with changes in expectations.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026